Cancer Treatment Reviews
Volume 31 , Pages S10-S16 , 2005

Fulvestrant (‘Faslodex’): Clinical experience from the Compassionate Use Programme

  • Guenther G. Steger

      Affiliations

    • Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, 18-20 Währinger Gürtel, A-1090 Vienna, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 140 400 5466; fax: +43 140 400 6081.
    • ,
  • Maya Gips

      Affiliations

    • Hadassah Medical Center, Jerusalem, Israel
    • ,
  • Sergio D. Simon

      Affiliations

    • Hospital Albert Einstein, São Paulo, Brazil
    • ,
  • Ana Lluch

      Affiliations

    • Hospital Clinico de Valencia, Valencia, Spain
    • ,
  • Jefferson Vinholes

      Affiliations

    • Santa Casa Hospital, Porto Alegre, Brazil
    • ,
  • Bella Kaufman

      Affiliations

    • The Chaim Sheba Medical Center, Tel-Hashomer, Israel
    • ,
  • Andrew Wardley

      Affiliations

    • Christie Hospital NHS Trust, Manchester, UK
    • ,
  • Louis Mauriac

      Affiliations

    • Institut Bergonié, Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, Bordeaux, France

References 

  1. Wakeling AE. Use of pure antioestrogens to elucidate the mode of action of oestrogens. Biochem Pharmacol. 1995;49:1545–1549
  2. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000;7:17–28
  3. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867–3873
  4. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396–3403
  5. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386–3395
  6. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women – a prospective combined analysis of two multicenter trials. Cancer. 2003;98:229–238
  7. Vergote I, Robertson JFR, Kleeberg U, Burton G, Osborne CK, Mauriac L. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003;79:207–211
  8. Robertson JFR, Howell A, Gorbunova VA, Watanabe T, Pienkowski T, Lichinitser MR. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat. 2005;92:169–174
  9. Perey L, Paridaens R, Nolé F, et al. Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat. 2004;88(Suppl. 1):S236;[abstr 6048]
  10. Ingle JN, Rowland KM, Suman VJ, et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Poster presentation at the San Antonio breast cancer symposium, 8–11 December 2004, San Antonio, Texas, USA [poster 409].
  11. Ingle JN, Rowland KM, Suman VJ, et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat. 2004;88(Suppl. 1):S38;[abstr 409]
  12. Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ, Osborne CK. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer. 2003;39:1228–1233
  13. Fernie NL, Zekri JM, Leonard RCF, Coleman RE, Cameron DA. Exemestane in metastatic breast cancer: effective therapy after 3rd generation aromatase inhibitor failure. Breast Cancer Res Treat. 2003;82(Suppl. 1):S104;[abstr 435]
  14. Howell A, Robertson JFR, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605–1613

PII: S0305-7372(05)00141-6

doi: 10.1016/j.ctrv.2005.08.009

Cancer Treatment Reviews
Volume 31 , Pages S10-S16 , 2005

Article Tools

* Image Usage & Resolution